Discontinuation of medication due to adverse events
Pembrolizumab showed no clear difference in discontinuation due to adverse event compared with chemotherapy (low certainty).
1 finding from 1 review
Serious adverse events (irrespective of attribution to treatment)
Pembrolizumab may leads to lower serious adverse events (irrespective of attribution to treatment) compared with chemotherapy (low certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
Combination probably leads to lower overall survival compared with single‐agent chemotherapy (moderate certainty).
1 finding from 1 review
Tumour response · people with advanced gastric cancer
Combination leads to higher tumour response compared with single‐agent chemotherapy (high certainty).
1 finding from 1 review
Time to progression · people with advanced gastric cancer
Combination probably leads to lower time to progression compared with single‐agent chemotherapy (moderate certainty).
1 finding from 1 review
Treatment‐related death · people with advanced gastric cancer
Combination showed no clear difference in treatment‐related death compared with single‐agent chemotherapy (moderate certainty).
1 finding from 1 review
All‐cause mortality · Patients with early unfavourable or advanced stage HL
Escalated BEACOPP leads to lower mortality compared with chemotherapy including ABVD (high certainty).
1 finding from 1 review
Relapse, progression or death (calculated instead of PFS) · Patients with early unfavourable or advanced stage HL
Escalated BEACOPP probably leads to lower progression, relapse or death compared with chemotherapy including ABVD (moderate certainty).
1 finding from 1 review
Adverse event: treatment‐related mortality · Patients with early unfavourable or advanced stage HL
Escalated BEACOPP showed no clear difference in adverse event: treatment‐related mortality compared with chemotherapy including ABVD (low certainty).
1 finding from 1 review
Adverse event: secondary malignancies · Patients with early unfavourable or advanced stage HL
Escalated BEACOPP showed no clear difference in adverse event: secondary malignancies compared with chemotherapy including ABVD (low certainty).
1 finding from 1 review
Adverse event: secondary malignancies: AML or MDS · Patients with early unfavourable or advanced stage HL
Escalated BEACOPP may leads to higher adverse event: secondary malignancies: AML or MDS compared with chemotherapy including ABVD (low certainty).
1 finding from 1 review
Adverse event: infertility (secondary amenorrhoea) · Patients with early unfavourable or advanced stage HL
It is very uncertain whether escalated BEACOPP changes adverse event: infertility (secondary amenorrhoea) compared with chemotherapy including ABVD (very low certainty).
1 finding from 1 review
Quality of life · Patients with early unfavourable or advanced stage HL
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (early stages)
Fewer showed no clear difference in secondary malignant neoplasms compared with more courses of chemotherapy (with or without radiotherapy (moderate certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (early stages)
Fewer showed no clear difference in death compared with more courses of chemotherapy (with or without radiotherapy (high certainty).
1 finding from 1 review
Progression/relapse · Patients with untreated Hodgkin lymphoma (early stages)
Fewer showed no clear difference in progression/relapse compared with more courses of chemotherapy (with or without radiotherapy (high certainty).
1 finding from 1 review
Nausea · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
1 finding from 1 review
Number of vomiting episodes · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found